Relmada Therapeutics Inc (RLMD) — Cash Flow-to-Debt Ratio
Relmada Therapeutics Inc (RLMD) has a Cash Flow-to-Debt Ratio of -0.91x as of March 2026, meaning its operating cash flow of $-15.07 Million could theoretically repay -1% of its total liabilities ($16.63 Million) in one year. Explore Relmada Therapeutics Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Relmada Therapeutics Inc Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Relmada Therapeutics Inc across 15 annual periods. Also explore total assets of Relmada Therapeutics Inc for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Relmada Therapeutics Inc (2012–2025)
Year-by-year debt coverage analysis for Relmada Therapeutics Inc. For market capitalisation and broader financial context, see Relmada Therapeutics Inc (RLMD) total market value.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -6.11x | $-45.79 Million | $7.49 Million | ▼ -21.6% |
| 2024 | -5.03x | $-51.76 Million | $10.30 Million | ▼ -18.7% |
| 2023 | -4.24x | $-51.66 Million | $12.19 Million | ▲ +49.1% |
| 2022 | -8.32x | $-103.80 Million | $12.47 Million | ▼ -36.5% |
| 2021 | -6.10x | $-91.87 Million | $15.06 Million | ▼ -176.5% |
| 2020 | -2.21x | $-27.81 Million | $12.60 Million | ▼ -26501.5% |
| 2019 | -0.01x | $-12.09K | $1.46 Million | ▲ +98.8% |
| 2018 | -0.70x | $-6.00 Million | $8.56 Million | ▲ +85.1% |
| 2017 | -4.70x | $-6.47 Million | $1.38 Million | ▼ -14.4% |
| 2016 | -4.11x | $-13.14 Million | $3.20 Million | ▼ -294.2% |
| 2015 | -1.04x | $-16.23 Million | $15.58 Million | ▲ +0.0% |
| 2014 | -1.04x | $-16.23 Million | $15.58 Million | ▼ -1149.3% |
| 2014 | -0.08x | $-2.24 Million | $26.87 Million | ▼ -18788.6% |
| 2013 | 0.00x | $-11.86K | $26.87 Million | ▲ +100.0% |
| 2012 | -1.08x | $-7.57K | $7.00K | — |